The Evaluation of p53 Polymorphism at Codon 72 and Association With Breast Cancer in Iran: A Systematic Review and Meta-analysis

Abozar Soleimani1, Yousef Rahmani2, Negin Farshchian3, Ali Delpisheh1, Kivan Khassi4, Afshar Shahmohammadi2, Nasrin Amirifard3

1Department of Epidemiology, Faculty of Health, Ilam University of Medical Sciences, Ilam, 2Clinical Research Development Center, Imam Ali and Taleghani Hospital, Kermanshah University of Medical Sciences, Kermanshah, 3Cancer Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, 4Province Health Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Background: Breast cancer is the most common cancer among women in Iran and the world. Multiple environmental factors and genetic variations such as genetic polymorphisms are of its main causes. p53 gene plays an important role in conserving and sustaining the genome as a tumor suppressing gene. Change and polymorphism at codon 72 of p53 gene are correlated with increased risk of lung, mouth, endometrial, prostate, and colorectal cancers, and could be considered an indicator of susceptibility to breast cancer.

Methods: Twelve studies (1,190 cases and 1,145 control studies with evaluation of three types of Arg/Arg, Arg/Pro, and Pro/Pro genotypes) have been conducted using keywords, such as polymorphism at codon 72, gene p53 polymorphisms, and the relation between polymorphisms and breast cancer, from databases in Iran, including Magiran, Medlibe, Sid, and Iranmedex, as well as Latin databases such as PubMed, Google Scholar, Science Direct, and Scopus.

Results: The OR for Arg/Arg is 1.58 (95% CI: 2.45 to 1.01), the OR for Arg/Pro is 0.75 (95% CI: 1.10 to 0.51), and the OR for Pro/Pro is 0.62 (95% CI: 0.93 to 0.42). p53 gene polymorphism at codon 72 is statistically significant in Arg/Arg and Pro/Pro genotypes.

Conclusions: Arg/Arg genotype can be considered as a risk factor for breast cancer, and Pro/Pro genotype can be accounted for as a protective factor against breast cancer.

(J Cancer Prev 2016;21:288-293)

Key Words: Breast neoplasms, Polymorphism, p53, Codon 72

INTRODUCTION

Breast cancer is among cancers with high prevalence and is the second most common cancer in women around the world.1,2 Thirty percent of all cancers and 15% of cancer-caused deaths among women are due to this cancer.3 According to the report of World Health Organization in February 2009, the annual breast cancer death rate is 519 thousand people worldwide.4 Breast cancer still has the first place in Iran regarding the population of the contracted.5 A total number of 40 thousand people are diagnosed with breast cancer in Iran and more than seven thousand patients are added to this number each year.6

In general, risk factors for breast cancer are unknown, but factors, such as family history, genetic background, age of menarche and menopause, age of first childbirth, hormone use, alcohol consumption, and previous history of cancer, can be considered.7 p53 gene polymorphism is one of the factors regarded by researchers as the cause of breast cancer. This gene with the length of 20 kilo-base pair is in 17p13.1 (short arm of chromosome 17) which contains 11 exons and its translated mRNA codes a protein with molecular weight of 53 kDa which contains 393 amino acids.8 Its normal function is to protect...
polymorphism and even reported different results in the relationship between breast cancer and some genotypes of this gene. Other studies from around the world also showed a significant relationship. Moreover, a great number of studies have been conducted to evaluate the role that these three genotypes play in breast cancer worldwide and have reported different results in this field. For example, the studies of Khadang et al., Kazemi et al., and Agorastos et al. in Greece and Vijayaraman et al. in southern part of Maduria found no significant relationship between polymorphism of this codon in p53 gene and breast cancer. In contrast, the studies of Sheikhpour and Zahir and Golmohammadi and Namazi showed a significant relationship. Moreover, a great number of other studies from around the world also showed a significant relationship between breast cancer and some genotypes of this polymorphism and even reported different results in the concluded meta-analysis in terms of the effect of different genotypes on breast cancer. The share of Iranian researches conducted on this subject matter was not more than two articles in these meta-analyses. These two articles were reasons enough for carrying out a structured review of studies conducted in this field in Iran to provide more reliable statistics of this category.

MATERIALS AND METHODS

The present study is to evaluate the rate of polymorphism of p53 gene codon 72 and its relationship to breast cancer risk in women. This has been carried out by collecting, documenting, employing case control studies that have been done in this area, and meta-analyzing the existing findings. Articles published in national and international journals in databases, such as Ranmedex, SID, Magiran, Irandoc, Science Direct, as well as articles presented at conferences or used to find surveys conducted in the country are of other sources on which this study has been constructed. Searching for relevant researches was performed through identifying Persian keywords with all of their possible combinations. Moreover, Persian keywords, such as polymorphism at codon 72, polymorphism of the gene p53, the relationship of polymorphisms and breast cancer, as well as English keywords including p53 polymorphism at codon 72, p53 polymorphism, and breast cancer, were used to increase the sensitivity of the present study. Finally, abstracts of researches were studied by the researchers based on inclusion and exclusion criteria after finding out the articles being concerned with codon 72 polymorphism and p53 gene polymorphism and selection of articles that had full connection with the research subject. Then, unrelated articles were excluded, and articles related to research were determined in order to download their full text and carry out extraction. The data of the prepared studies were extracted after entering selected articles into the study and approving the quality control using pre-prepared checklist. The prepared checklist was used to extract data using factors such as: article’s title, the first author, the rank of the article, the research date, the total sampling size in case and control groups, and the ratio of each of the three Arg/Arg, Arg/Pro, and Pro/Pro genotypes in both case and control groups. All data were extracted from the studies and were entered into the mentioned form.

Fifty-four articles were examined in this process. After that, 25 articles which included the basic information were fully studied. Then, 17 articles were removed due to being about the effect of this gene on other cancers and being conducted in other countries. Finally, 12 articles that were conducted on Iranian women between 2007 and 2014 were included into the analysis process.

In this step, all cross-sectional studies in the field of gene p53 polymorphism at codon 72 and its relation with breast cancer risk in Iran, which all were cross-sectional studies, were collected and given that the prevalence of polymorphism had binomial distribution in both groups. The variance of each study was calculated through binomial distribution variance. Weight given to each study was inversely proportional to the variance. and I² index was used to evaluate heterogeneity between data. Data analysis was done using Stata ver. 11 software (Stata Corp, College Station, TX, USA). P lower than 0.05 was considered to be significant in the case of heterogeneity test.

RESULTS

In this research, the highest OR of developing breast cancer was detected in people with Arg/Arg genotype as a research of Faghani et al. demonstrated and the OR was related to the study of GhasemiFirouzabadi et al. Of these 12 studies, 7 studies reported that the OR of developing breast cancer in Arg/Arg genotype is significant. Six studies reported Arg/Arg
genotype as a disposing factor for breast cancer and Ghaseemifirouzabadi et al. reported this genotype as a protective factor against cancer in women. Other inquiries have not discovered any significant relationship between Arg/Arg genotype and breast cancer risk (Table 1). \(^{13,14,17-31}\)

However, it was determined after a meta-analysis that the OR of developing breast cancer in Iranian women with Arg/Arg genotype is 1.58 (95% CI: 1.01 to 2.45) (Fig. 1).

Five studies were statistically significant in evaluation of OR of developing breast cancer in patients with Arg/Pro genotype. Only the study of Boroujeni et al. \(^{31}\) reported the role of Arg/Pro genotype as a risk factor for cancer, and the other four \(^{17,24,26,28}\) recorded this genotype as a protective factor against breast cancer. However, other studies did not account for a significant relationship between Arg/Arg genotype and breast cancer risk. It was decided after the meta-analysis that the OR of developing breast cancer in people with Arg/Pro genotype is 0.75 (95% CI: 0.51 to 1.10) (Fig. 2).

It was confirmed from the evaluation of concluded studies in the field of p53 gene codon 72 polymorphism, its relationship with breast cancer risk in Iran, and the role of Pro/Pro genotype in breast cancer risk that 4 studies out of these 12 studies were statistically meaningful: only the study of Kazemi et al. \(^{14}\) reported the existence of Pro/Pro genotype in individuals as a factor that stimulates breast cancer, and other three studies noted that this genotype is a securing agent against breast cancer. No compelling relationship was established between Pro/Pro genotype and breast cancer risk in other studies. After carrying out the meta-analysis and the evaluation of each study in Iran, it was determined that the OR of developing breast cancer in people

---

**Table 1.** Reviewed articles on p53 gene codon 72 polymorphism and its association with breast cancer risk in Iran

| First author | Year | Location study | Case (n) | Control (n) | OR (95% CI) |
|--------------|------|----------------|---------|------------|-------------|
| Faghani \(^{24}\) | 2007 | Esfahan | 51 | 51 | 0.400 (0.043-5.580) |
| Yasebi \(^{29}\) | 2007 | Chaharmahal | 85 | 50 | 0.384 (0.115-1.282) |
| Khadang \(^{13}\) | 2007 | Entire country | 221 | 205 | 0.623 (0.370-1.049) |
| Faghani \(^{26}\) | 2008 | Esfahan | 96 | 96 | 0.365 (0.144-0.927) |
| Kazemi \(^{14}\) | 2009 | Northern Iran | 42 | 57 | 20.47 (1.120-374.5) |
| Doosti \(^{27}\) | 2011 | Entire country | 135 | 140 | 0.572 (0.275-1.187) |
| Hossein Pour Feizi \(^{28}\) | 2012 | Eastern Azerbaijan | 126 | 99 | 1.095 (0.565-2.119) |
| Ghaseemifirouzabadi \(^{25}\) | 2013 | Yazd | 90 | 83 | 1.476 (0.785-2.778) |
| Boroujeni \(^{31}\) | 2013 | Central Iran | 135 | 150 | 0.286 (0.112-0.731) |
| Golmohammadi \(^{28}\) | 2013 | Sabzevar | 80 | 80 | 0.121 (0.027-0.551) |
| Behfarjam \(^{30}\) | 2013 | Mahabad | 25 | 30 | 0.565 (0.095-3.378) |
| Sheikhpour \(^{17}\) | 2014 | Yazd | 104 | 104 | 0.728 (0.384-1.381) |

**Figure 1.** The OR of developing breast cancer in patients with Arg/Arg genotype in the Iran.
Figure 2. The OR of developing breast cancer in patients with Arg/Pro genotype in the Iran.

Figure 3. The OR of developing breast cancer in patients with Pro/Pro genotype in the Iran.

with Pro/Pro genotype is 0.62 (95% CI: 0.42 to 0.93) (Fig. 3).

Egger test was used to evaluate publication bias to find out whether this bias has affected the results, and the diagram 4 shows that publication bias has not affected the obtained results (Fig. 4).

**DISCUSSION**

Numerous studies have been carried out in the field of p53 codon 72 polymorphism and its correspondence with breast cancer risk throughout the world. Some of these studies believe that changes in a particular p53 gene codon 72 genotype predispose females to breast cancer, and other studies have considered the same change as a preventing factor. Meta-analyses have been done within this domain in different races, among which there are only two Iranian studies. However, there is no analysis along with statistical weighting for concluded studies in Iran in order to have a comprehensive perception on the role of this polymorphism in risk of breast cancer in Iranian women. The OR of breast cancer for three Arg/Arg, Arg/Pro, and Pro/Pro genotypes were calculated in the present research. OR of developing breast cancer in Iranian women with genotype Arg/Arg is 1.58 (95% CI: 1.01 to 2.45). This can be statistically considered as a predisposing factor for developing breast cancer in Iranian women because OR does not contain number 1. This result is in tandem with the studies of Doosti et al.27 and Hossein Pour Feizi et al.28 Meta-analyses of Gonçalves et al.23 and Buyru et al.32 concluded in a study conducted in Turkey that the risk of
landscape

The OR of developing breast cancer in patients with Arg/Pro genotype was 0.75 (95% CI: 0.51 to 1.10). Arg/Pro genotype has no effect on the risk of breast cancer which is in line with the results of many domestic studies, such as Doosti et al.27 and foreign researches of Hou et al.33

After examining the results of the aforementioned studies, it was determined that the OR of developing breast cancer in people with Pro/Pro genotype is 0.62 (95% CI: 0.42 to 0.93). This was statically important because the OR does not contain 1, in a way that Pro/Pro genotype can be regarded as a protective factor against breast cancer in Iranian women. This accords with the study results of Sheikhpour and Zahir17 and Faghani et al.,26 and Alawadi et al.34 who concluded that the risk of breast cancer is lower among Arab women with Pro/Pro genotype.

At the end, it should be noted that due to the scarcity of studies in this field in Iran, it is required for direct studies about p53 gene codon 72 polymorphism and its relationship to breast cancer risk in Iran so that the obtained results can be used clearly and more importantly.

CONFLICTS OF INTEREST

No potential conflicts of interest were disclosed.

REFERENCES

1. Vogel VG. Breast cancer prevention: a review of current evidence. CA Cancer J Clin 2000;50:156-70.
2. Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA, et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996;88:1571-9.
3. Ghafoor A, Jemal A, Ward E, Colleizes V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2005;55:54-55.
4. World Health Organization (WHO). Fact sheet No297. Geneva. WHO, 2015.
5. Bremadi K, Goya M. National Report on Cancer Registration in 2009 year. Tehran, Ministry of Health, pp 16, 2012.
6. Pezeshkianbedoosmarz [Persian], http://www.pezeshk.us/?p=23919. Accessed July 29, 2010.
7. Wolff MS, Weston A. Breast cancer risk and environmental exposures. Environ Health Perspect 1997;105 Suppl 4:891-6.
8. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A 1991;88:5006-10.
9. Thomas M, Kalita A, Labebeque P, Simon D, Banks L, Matalashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
10. Nikbakht Dastjerdi M, Aboutorabi R, Islami Farsangi B. Association of TP53 gene codon 72 polymorphism with endometriosis risk in Isfahan, Iran J Reprod Med 2013;11:473-8.
11. Pietsch EC, Humboe Y, Murphy MB. Polymorphisms in the p53 pathway. Oncogene 2000;25:1602-11.
12. Khadang B, Fattahi MJ, Talei A, Dehaghians AS, Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 2007;173:38-42.
13. Kazemi M, Salehi Z, Chalosani RJ. TP53 codon 72 polymorphism and breast cancer in northern Iran. Oncol Res 2009;19:25-30.
14. Agorastos T, Masouridou S, Lambropoulos AF, Chriafi S, Miliaras D, Pantazis K, et al. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 2004;13:277-80.
15. Vijayaraman KP, Veluchamy M, Murugesan F, Shammughap KP, Kasi PD. p53 exon 4 (codon 72) polymorphism and exon 7 (codon 249) mutation in breast cancer patients in southern region (Madurai) of Tamil Nadu. Asian Pac J Cancer Prev 2012;13:511-6.
16. Sheikhpour R, Zahir ST. Evaluation of Tp53 codon 72 polymorphism and resulted protein in breast cancer patients in Yazd city. Iran J Breast Dis 2014;7:20-9.
17. Golmohammadi R, Namazi MJ. The role of p53 codon 72 genotype in ductal breast carcinoma. Feyz J Kashan Univ Med Sci 2013;17:387-93.
18. Proestling K, Hebar A, Pruckner N, Marton E, Vinatzer U, Schreiber M. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS One 2012;7:e47325.
19. Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, et al. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 2006;30:523-9.
20. Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000;3:389-92.
21. Proestling K, Hebar A, Pruckner N, Marton E, Vinatzer U, Schreiber M. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS One 2012;7:e47325.
22. Zhuo W, Zhang Y, Xiang Z, Cai L, Chen Z. Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls. J Exp Clin Cancer Res 2009;28:115.
Vilanova-Costa CA, et al. Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis. Springerplus 2014;3:749.

24. Faghani M, NikbakhtDastjerdi M, Salehi M, Rabbani M, Talebi A, Faghihi M, et al. Study of p53 polymorphism at codon 72 in patients of breast cancer in Isfahan. J Isfahan Med Sch 2007; 25:26-33.

25. Ghasemifirouzabadi N, Shyryzdy M, Ksharzy F, Dhqanmnshady M, arasthkny A, Sadat Hosseini S, et al. Frequency of P53 gene codon 72 polymorphism in people with and without breast cancer. In: Publications PM, ed. Eighth International Conference on Breast Cancer. Tehran, Professional Media Publications. pp 145. 2013.

26. Faghani M, Nasiri E, Bahadori MH, Mohammad Ghasemi F. Genetic predisposing of P53 codon 72 on developing of breast cancer in postmenopausal women in Isfahan. J Guilan Univ Med Sci 2008;17:94-100.

27. Doosti A, Ghasemi-Dehkordi P, Davoudi N. A p53 codon 72 polymorphism associated with breast cancer in Iranian patients. Afr J Pharm Pharmacol 2011;5:1278-81.

28. Hossein Pour Feizi MA, RavanbakhshGavagni R, Pourahmad R, Pouladi N, Azarfam P, Montazeri V. Association of p53 Arg/Pro polymorphism at codon 72 with risk of breast cancer in east azerbaijani women. J Babol Univ Med Sci 2012;14:31-8.

29. Yasebi A, Doosti A. A p53 codon 72 polymorphism associated with breast cancer. In: sciences mmou, ed. 18th Congress of Physiology and Pharmacology. Mashhad. Mashad Medical of University Sciences. 2007.

30. Behfarjam F, Rostamzadeh J, Jian F. Study of TP53 codon 72 & 282 polymorphisms and ABCC1 promoter polymorphism (G-1666A) in archived breast cancer samples mahabadian women by PCR-RFLP and PCR-SSCP. In: Publication PM ed. Eighth International Conference on Breast Cancer. Tehran. Professional Media Publications. pp 487. 2013.

31. Boroujeni HR, Karimi M, Moshkelani S, Parsaei P. Association of the p53 codon 72 polymorphism with breast cancer in central part of Iran. Afr J Pharm Pharmacol 2013;7:356-9.

32. Buyru N, Tigli H, Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep 2003;10:711-4.

33. Hou J, Jiang Y, Tang W, Jia S. p53 codon 72 polymorphism and breast cancer risk: ameta-analysis. Exp Ther Med 2013;5:1397-402.

34. Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Akil N, et al. P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol 2011;28:709-15.